Although clinical benefit from SMO inhibitors has been established in basal cell carcinoma (BCC) 119, 120 and medulloblastoma 121, their use in other solid tumors including colorectal, pancreatic, or lung cancer has been disappointing 122, 123, 124. This evidence concerns the gene SMO and lung cancer.